Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Insider Sells 5,000 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) insider Juan Andres sold 5,000 shares of the business’s stock in a transaction dated Friday, November 26th. The stock was sold at an average price of $319.62, for a total value of $1,598,100.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Juan Andres also recently made the following trade(s):

  • On Monday, November 29th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $370.38, for a total value of $1,851,900.00.
  • On Wednesday, November 24th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $273.01, for a total value of $1,365,050.00.
  • On Monday, November 22nd, Juan Andres sold 15,000 shares of Moderna stock. The shares were sold at an average price of $268.18, for a total value of $4,022,700.00.
  • On Friday, November 19th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $265.71, for a total value of $1,328,550.00.
  • On Wednesday, November 17th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $234.57, for a total value of $1,172,850.00.
  • On Monday, November 15th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $231.01, for a total value of $1,155,050.00.
  • On Wednesday, November 10th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $230.00, for a total value of $1,150,000.00.
  • On Friday, November 5th, Juan Andres sold 5,000 shares of Moderna stock. The shares were sold at an average price of $240.00, for a total value of $1,200,000.00.
  • On Monday, November 8th, Juan Andres sold 15,000 shares of Moderna stock. The stock was sold at an average price of $233.13, for a total value of $3,496,950.00.
  • On Monday, November 1st, Juan Andres sold 5,000 shares of Moderna stock. The stock was sold at an average price of $335.00, for a total value of $1,675,000.00.

Moderna stock opened at $310.61 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.25 and a current ratio of 1.35. The firm has a market capitalization of $125.94 billion, a price-to-earnings ratio of 19.04, a price-to-earnings-growth ratio of 0.43 and a beta of 1.32. Moderna, Inc. has a fifty-two week low of $102.66 and a fifty-two week high of $497.49. The stock’s fifty day moving average is $315.24 and its two-hundred day moving average is $308.29.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 4th. The company reported $7.70 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $9.49 by ($1.79). The firm had revenue of $4.97 billion during the quarter, compared to analyst estimates of $6.29 billion. Moderna had a net margin of 59.69% and a return on equity of 121.61%. The firm’s revenue for the quarter was up 3065.0% on a year-over-year basis. During the same period last year, the company posted ($0.59) EPS. As a group, sell-side analysts forecast that Moderna, Inc. will post 26.58 EPS for the current fiscal year.

Several research firms have recently commented on MRNA. Wolfe Research began coverage on Moderna in a research note on Monday, November 8th. They set an “outperform” rating and a $304.00 price target for the company. TheStreet upgraded Moderna from a “c+” rating to a “b-” rating in a research note on Monday, November 1st. Piper Sandler cut their price objective on Moderna to $348.00 and set an “overweight” rating for the company in a research report on Friday, November 5th. SVB Leerink increased their price objective on Moderna from $85.00 to $86.00 and gave the stock an “underperform” rating in a research report on Friday, November 5th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Moderna in a research report on Friday, October 22nd. They issued a “sell” rating and a $250.00 price objective for the company. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $243.93.

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. Coatue Management LLC boosted its stake in shares of Moderna by 388.3% during the second quarter. Coatue Management LLC now owns 6,140,904 shares of the company’s stock valued at $1,442,990,000 after acquiring an additional 4,883,219 shares during the last quarter. Lone Pine Capital LLC acquired a new stake in shares of Moderna during the second quarter valued at $937,781,000. Geode Capital Management LLC boosted its stake in shares of Moderna by 71.6% during the third quarter. Geode Capital Management LLC now owns 5,759,961 shares of the company’s stock valued at $2,210,437,000 after acquiring an additional 2,404,103 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Moderna by 94.9% during the second quarter. Renaissance Technologies LLC now owns 3,188,454 shares of the company’s stock valued at $749,223,000 after acquiring an additional 1,552,925 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of Moderna by 30,664.5% during the second quarter. Macquarie Group Ltd. now owns 1,514,535 shares of the company’s stock valued at $355,886,000 after acquiring an additional 1,509,612 shares during the last quarter. 55.10% of the stock is currently owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Article: What is a support level?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.